Treatment of intraventricular hemorrhage in the premature infant with urokinase. A preliminary report.
Hydrocephalus secondary to intraventricular hemorrhage in the premature infant is common and is secondary to the presence of blood in the subarachnoid space. Rapid clearance of the blood may reduce the incidence of permanent hydrocephalus and mitigate the need for shunt placement. We have treated 4 premature infants with posthemorrhagic hydrocephalus with urokinase, a thrombolytic agent, instilled into the ventricles via a surgically paced ventricular access device. The infants were treated with 10,000 IU of urokinase twice a day for 1 week. No adverse reactions have occurred and none of the infants has required shunt placement. In a group of historical controls, the shunt rate was 87%.
Hudgins
R J
RJ
Scottish Rite Children's Medical Center, Department of Neurosurgery, Atlanta, GA 30342.
Boydston
W R
WR
Hudgins
P A
PA
Adler
S R
SR
D001724:Birth Weight; D002543:Cerebral Hemorrhage / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D002552:Cerebral Ventricles / Q000000981:diagnostic imaging / Q000503:physiopathology* / Q000601:surgery; D005260:Female; D005865:Gestational Age; D006801:Humans; D006849:Hydrocephalus / Q000503:physiopathology / Q000601:surgery; D007231:Infant, Newborn; D007234:Infant, Premature; D007276:Injections, Intraventricular; D008297:Male; D012720:Severity of Illness Index; D014463:Ultrasonography; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*; D017287:Ventriculoperitoneal Shunt
D014568:Urokinase-Type Plasminogen Activator